[go: up one dir, main page]

PE20060311A1 - Formulacion en aerosol para la inhalacion de beta-agonistas - Google Patents

Formulacion en aerosol para la inhalacion de beta-agonistas

Info

Publication number
PE20060311A1
PE20060311A1 PE2005000529A PE2005000529A PE20060311A1 PE 20060311 A1 PE20060311 A1 PE 20060311A1 PE 2005000529 A PE2005000529 A PE 2005000529A PE 2005000529 A PE2005000529 A PE 2005000529A PE 20060311 A1 PE20060311 A1 PE 20060311A1
Authority
PE
Peru
Prior art keywords
hydroxy
dimethyl
acid
formulation
beta
Prior art date
Application number
PE2005000529A
Other languages
English (en)
Inventor
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060311(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060311A1 publication Critical patent/PE20060311A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04Amoebicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA EN AEROSOL SIN GAS PROPELENTE QUE COMPRENDE a) COMO PRINCIPIO ACTIVO UN COMPUESTO BETA-AGONISTA DE FORMULA (I), EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C4), ALCOXI(C1-C4) O HALOGENO; R3 ES R1 O R2, OH, -O-ALQUILEN(C1-C4)-COOH U -O-ALQUILEN(C1-C4)-ALQUILO(C1-C4); X- ES CLORURO, BROMURO, SULFATO, METANSULFONATO, MALEATO, ACETATO, ENTRE OTROS. SON PREFERIDOS: 6-HIDROXI-8-{1-HIDROXI-2,6-DIMETIL-FENIL)-1,1-DIMETIL-ETILAMINO]-ETIL}-4H-BENZO[1,4]OXAZIN-3-ON-METANOSULFONATO, SAL POR ADICION DE ACIDO DE 8-{2-[2-(4-FLUORO-FENIL)-1,1-DIMETIL-ETILAMINO}-1-HIDROXI-ETIL}-6*-HIDROXI-4H-BENZO[1,4}OXAZIN-3-ONA, ENTRE OTROS; b) AL MENOS UN ACIDO INORGANICO TAL COMO ACIDO CLORHIDRICO, BROMHIDRICO, NITRICO, ENTRE OTROS O UN ACIDO ORGANICO TAL COMO ACIDO ASCORBICO, CITRICO, MALICO, TARTARICO, ENTRE OTROS; c) EVENTULAMENTE COADYUVANTES COMO CLORURO DE BENZALCONIO Y/O FORMADORES DE COMPLEJOS Y d) COMO DISOLVENTES AGUA O ETANOL O UNA MEZCLA DE ESTOS. ESTA FORMULACION TIENE UN VALOR pH DE 2,5 A 6,5 Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DE LAS VIAS RESPIRATORIAS COMO ASMA, ENFERMEDADES PULMONARES OBSTRUCTIVAS. TAMBIEN SE REFIERE A UN KIT DE INHALACION QUE COMPRENDE LA FORMULACION Y UN INHALADOR PARA LA NEBULIZACION (RESPIMAT)
PE2005000529A 2004-05-14 2005-05-12 Formulacion en aerosol para la inhalacion de beta-agonistas PE20060311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004024452A DE102004024452A1 (de) 2004-05-14 2004-05-14 Aerosolformulierung für die Inhalation von Betaagonisten

Publications (1)

Publication Number Publication Date
PE20060311A1 true PE20060311A1 (es) 2006-05-08

Family

ID=34979667

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000529A PE20060311A1 (es) 2004-05-14 2005-05-12 Formulacion en aerosol para la inhalacion de beta-agonistas

Country Status (26)

Country Link
EP (1) EP1809293B1 (es)
JP (1) JP4620730B2 (es)
KR (1) KR101288791B1 (es)
CN (1) CN101056640A (es)
AR (1) AR049096A1 (es)
AU (1) AU2005244414B2 (es)
BR (1) BRPI0511135B8 (es)
CA (1) CA2564379C (es)
DE (1) DE102004024452A1 (es)
DK (1) DK1809293T3 (es)
EA (1) EA012583B1 (es)
EC (1) ECSP067004A (es)
ES (1) ES2575925T3 (es)
HU (1) HUE027780T2 (es)
IL (1) IL179218A (es)
MX (1) MXPA06013216A (es)
MY (1) MY148403A (es)
NO (1) NO20065030L (es)
PE (1) PE20060311A1 (es)
PL (1) PL1809293T3 (es)
SG (1) SG152265A1 (es)
TW (1) TWI356703B (es)
UA (1) UA87312C2 (es)
UY (1) UY28891A1 (es)
WO (1) WO2005110421A2 (es)
ZA (1) ZA200607462B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
JP5270343B2 (ja) 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータミメティックスの製造方法
JP2009514933A (ja) * 2005-11-09 2009-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入用エアロゾル製剤
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
CA2738617A1 (en) * 2008-11-21 2011-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
CA2738616A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
EP4069669A1 (en) * 2019-12-05 2022-10-12 Syngenta Crop Protection AG One step process for the preparation of phenyl ethyl amine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPH0637388B2 (ja) * 1986-02-17 1994-05-18 千寿製薬株式会社 水性液剤
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PL1781298T4 (pl) * 2004-04-22 2017-07-31 Boehringer Ingelheim International Gmbh Kombinacje leków zawierające benzoksazynę do leczenia chorób dróg oddechowych
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2564379A1 (en) 2005-11-24
JP4620730B2 (ja) 2011-01-26
AU2005244414A1 (en) 2005-11-24
CA2564379C (en) 2013-07-30
DK1809293T3 (en) 2016-06-20
WO2005110421A3 (de) 2006-03-16
DE102004024452A1 (de) 2005-12-08
TWI356703B (en) 2012-01-21
ZA200607462B (en) 2008-06-25
MY148403A (en) 2013-04-30
BRPI0511135B1 (pt) 2019-11-12
SG152265A1 (en) 2009-05-29
HUE027780T2 (en) 2016-11-28
EP1809293A2 (de) 2007-07-25
IL179218A (en) 2012-10-31
TW200608981A (en) 2006-03-16
EP1809293B1 (de) 2016-03-16
JP2007537188A (ja) 2007-12-20
BRPI0511135A (pt) 2007-11-27
KR20070022084A (ko) 2007-02-23
MXPA06013216A (es) 2007-02-08
WO2005110421A2 (de) 2005-11-24
CN101056640A (zh) 2007-10-17
KR101288791B1 (ko) 2013-07-29
NO20065030L (no) 2006-11-30
IL179218A0 (en) 2007-03-08
ES2575925T3 (es) 2016-07-04
BRPI0511135B8 (pt) 2021-05-25
EA012583B1 (ru) 2009-10-30
UA87312C2 (ru) 2009-07-10
EA200602017A1 (ru) 2007-06-29
ECSP067004A (es) 2007-02-28
AU2005244414B2 (en) 2010-12-09
AR049096A1 (es) 2006-06-28
PL1809293T3 (pl) 2016-09-30
UY28891A1 (es) 2005-12-30

Similar Documents

Publication Publication Date Title
ES2399179T3 (es) Tratamiento de enfermedad respiratoria
PE20081319A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
PE20060311A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
EA025158B1 (ru) Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения
MEP51008A (en) Aerosol formulation for inhalation, containing an anticholinergic agent
US20110135582A1 (en) Combination of medicaments for the treatment of respiratory diseases
ES2380370T3 (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
ES2668364T3 (es) Formulación en aerosol para la inhalación de beta-agonistas
JP2007533683A5 (es)
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
US20100040559A1 (en) Use of a Pharmaceutical Composition Comprising an Anticholinergic for Killing Microorganisms and for Treating Respiratory Tract Infections
PE20040326A1 (es) Medicamento que contiene esteroides y un nuevo anticolinergico
EA200401305A1 (ru) Аэрозольная композиция для ингаляции, содержащая соль тиотропия
PE20080425A1 (es) Formulacion aerosol para la inhalacion de beta-agonistas
JP2009537585A (ja) 呼吸器疾患の治療のための新規医薬組成物
KR20080024532A (ko) 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물
AR038764A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
ES2442343T3 (es) Compuestos de sulfonamida para el tratamiento de trastornos respiratorios
JP2011502967A (ja) β模倣薬の結晶性水和物及びその薬剤としての使用
JP2009514933A (ja) 吸入用エアロゾル製剤
US20110319402A1 (en) Aerosol formulation for the inhalation of beta agonists
CA2650813A1 (en) New long-acting drug combinations for the treatment of respiratory diseases
US20100015061A1 (en) Pharmaceutical Compositions Based on Anticholinergics and Andolast
PE20040327A1 (es) Medicamento que contiene betamimeticos y un nuevo anticolinergico
US20050042176A1 (en) Medicaments for inhalation comprising a novel anticholinergic and a steroid

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed